Published in PLoS One on July 16, 2008
Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One (2010) 1.75
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol (2012) 1.71
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One (2012) 1.70
Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol (2012) 1.69
Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol (2010) 1.61
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol (2013) 1.59
Comparison of molecular signatures from multiple skin diseases identifies mechanisms of immunopathogenesis. J Invest Dermatol (2014) 1.56
Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol (2009) 1.54
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol (2015) 1.47
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol (2012) 1.46
Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms. J Invest Dermatol (2014) 1.36
Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics (2013) 1.32
Random generalized linear model: a highly accurate and interpretable ensemble predictor. BMC Bioinformatics (2013) 1.29
Microbiomic signatures of psoriasis: feasibility and methodology comparison. Sci Rep (2013) 1.24
Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc Natl Acad Sci U S A (2013) 1.24
Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. J Invest Dermatol (2012) 1.20
Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One (2012) 1.11
Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A (2012) 1.10
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol (2009) 1.08
Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS One (2013) 1.07
Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Hum Mol Genet (2012) 1.06
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis (2013) 1.06
Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol (2009) 1.05
Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther (2010) 1.03
Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. Genome Biol (2015) 1.03
Marginal zone precursor B cells as cellular agents for type I IFN-promoted antigen transport in autoimmunity. J Immunol (2009) 1.02
Cigarette smoke attenuates the production of cytokines by human plasmacytoid dendritic cells and enhances the release of IL-8 in response to TLR-9 stimulation. Respir Res (2009) 1.01
Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS One (2012) 1.00
Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PLoS One (2013) 0.99
The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun (2015) 0.95
Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. Hum Mol Genet (2011) 0.95
Genomic profiling of human Leishmania braziliensis lesions identifies transcriptional modules associated with cutaneous immunopathology. J Invest Dermatol (2014) 0.94
Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-β autocrine signaling to promote monocyte recruitment. Immunity (2013) 0.93
Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era. BMC Med Genomics (2014) 0.93
Integrated network analysis of transcriptomic and proteomic data in psoriasis. BMC Syst Biol (2010) 0.91
Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther (2014) 0.90
Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol (2012) 0.88
Cross-study homogeneity of psoriasis gene expression in skin across a large expression range. PLoS One (2013) 0.88
Multi-TGDR: a regularization method for multi-class classification in microarray experiments. PLoS One (2013) 0.88
Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN. BMC Genomics (2015) 0.88
Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome. Ann Rheum Dis (2015) 0.87
Cross-Disease Transcriptomics: Unique IL-17A Signaling in Psoriasis Lesions and an Autoimmune PBMC Signature. J Invest Dermatol (2016) 0.87
Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics (2012) 0.87
Integrative RNA-seq and microarray data analysis reveals GC content and gene length biases in the psoriasis transcriptome. Physiol Genomics (2014) 0.86
Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev (2012) 0.86
Proteomics of skin proteins in psoriasis: from discovery and verification in a mouse model to confirmation in humans. Mol Cell Proteomics (2014) 0.86
Genome-wide analysis of the genetic regulation of gene expression in human neutrophils. Nat Commun (2015) 0.85
Psoriasis. Cold Spring Harb Perspect Med (2014) 0.85
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. J Invest Dermatol (2016) 0.85
Genome-wide transcriptional analysis of T cell activation reveals differential gene expression associated with psoriasis. BMC Genomics (2013) 0.84
Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. Clin Transl Med (2015) 0.84
A GRHL3-regulated repair pathway suppresses immune-mediated epidermal hyperplasia. J Clin Invest (2014) 0.84
Patterns and functional roles of LINE-1 and Alu methylation in the keratinocyte from patients with psoriasis vulgaris. J Hum Genet (2015) 0.82
Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution. Cell Syst (2015) 0.82
Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice. Immunology (2010) 0.81
Germinal center B cell depletion diminishes CD4+ follicular T helper cells in autoimmune mice. PLoS One (2014) 0.81
Genomic signatures characterize leukocyte infiltration in myositis muscles. BMC Med Genomics (2012) 0.80
Computational approach to identify enzymes that are potential therapeutic candidates for psoriasis. Enzyme Res (2011) 0.80
Microarray analyses demonstrate the involvement of type I interferons in psoriasiform pathology development in D6-deficient mice. J Biol Chem (2013) 0.80
Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach. PLoS One (2013) 0.80
EBI2 is a negative regulator of type I interferons in plasmacytoid and myeloid dendritic cells. PLoS One (2013) 0.79
Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol (2015) 0.78
ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. Oncotarget (2016) 0.78
Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications. PLoS One (2015) 0.77
SRSF1 facilitates cytosolic DNA-induced production of type I interferons recognized by RIG-I. PLoS One (2015) 0.77
Study on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms. Open Biochem J (2014) 0.76
Therapeutic targeting of the inflammome. Biochem Pharmacol (2014) 0.76
Computational Systems Biology of Psoriasis: Are We Ready for the Age of Omics and Systems Biomarkers? OMICS (2015) 0.75
Derivation of marker gene signatures from human skin and their use in the interpretation of the transcriptional changes associated with dermatological disorders. J Pathol (2017) 0.75
Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma. Pharmaceutics (2016) 0.75
Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury. Immunity (2016) 0.75
Study of Molecular Mechanisms Involved in the Pathogenesis of Immune-Mediated Inflammatory Diseases, using Psoriasis As a Model. Acta Naturae (2009) 0.75
Pathway activity inference for multiclass disease classification through a mathematical programming optimisation framework. BMC Bioinformatics (2014) 0.75
Hypomorphic A20 expression confers susceptibility to psoriasis. PLoS One (2017) 0.75
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature (2005) 13.23
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
IRF family of transcription factors as regulators of host defense. Annu Rev Immunol (2001) 8.18
Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med (1999) 8.01
Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol (2005) 7.74
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med (2005) 4.04
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A (2005) 3.74
Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell (1990) 3.58
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol (2005) 3.07
Psoriasis. Lancet (2003) 3.05
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol (2004) 2.96
Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum (2005) 2.42
Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol (2003) 2.21
The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol (2002) 2.15
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A (2005) 2.12
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96
Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol (2005) 1.95
Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol (2004) 1.92
Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol (2007) 1.69
CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity (2000) 1.57
Analysis of functional domains of interferon regulatory factor 7 and its association with IRF-3. Virology (2001) 1.39
Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol (2007) 1.36
Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol (2000) 1.26
Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol (2005) 1.12
In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol (2004) 1.08
Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine (2006) 1.06
Psoriasis induced by interferon-alpha. Br J Dermatol (1991) 1.04
Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol (2004) 0.99
Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol (2005) 0.93
The type I interferon system is locally activated in psoriatic lesions. J Interferon Res (1994) 0.92
Psoriasis exacerbation induced by interferon-alpha. Report of two cases. Acta Derm Venereol (1993) 0.92
In situ localization of interferons in psoriatic lesions. Arch Dermatol Res (1989) 0.82
Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol (2006) 10.55
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86
Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med (2009) 2.61
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system. Proc Natl Acad Sci U S A (2007) 2.46
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med (2010) 2.36
Distinct roles of TLR2 and the adaptor ASC in IL-1beta/IL-18 secretion in response to Listeria monocytogenes. J Immunol (2006) 2.21
The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis. J Biol Chem (2003) 2.18
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 2.17
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum (2009) 2.14
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem (2001) 2.07
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum (2013) 2.06
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis (2011) 1.91
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol (2010) 1.86
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol (2005) 1.80
YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol (2008) 1.78
PAK4 mediates morphological changes through the regulation of GEF-H1. J Cell Sci (2005) 1.75
Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol (2006) 1.73
Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum (2007) 1.72
Gene expression and genetic variation data implicate PCLO in bipolar disorder. Biol Psychiatry (2010) 1.70
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62
Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol (2003) 1.57
Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus. Arthritis Rheum (2012) 1.54
The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol (2003) 1.52
The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp Hematol (2002) 1.48
The plasma cell signature in autoimmune disease. Arthritis Rheumatol (2014) 1.47
Retracted Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A (2002) 1.41
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol (2010) 1.41
Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol (2003) 1.38
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis (2011) 1.37
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum (2007) 1.35
Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother (2005) 1.32
Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol (2003) 1.31
Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med (2009) 1.29
Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev (2003) 1.25
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res (2008) 1.25
Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol (2002) 1.23
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood (2002) 1.22
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res (2011) 1.22
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Hum Genomics Proteomics (2009) 1.22
Body image dissatisfaction among women with scleroderma: extent and relationship to psychosocial function. Health Psychol (2003) 1.21
Genomic signatures of strain selection and enhancement in Bacillus atrophaeus var. globigii, a historical biowarfare simulant. PLoS One (2011) 1.21
Regulation of CovR expression in Group B Streptococcus impacts blood-brain barrier penetration. Mol Microbiol (2010) 1.18
An anti-inflammatory role for plasmacytoid dendritic cells in allergic airway inflammation. J Immunol (2009) 1.17
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2006) 1.16
Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol (2010) 1.16
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res (2007) 1.15
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol (2009) 1.14
Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis (2008) 1.13
Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci (2007) 1.12
Differential EphA2 epitope display on normal versus malignant cells. Cancer Res (2003) 1.12
Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol (2009) 1.11
Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One (2012) 1.11
The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn). Oncogene (2002) 1.11
Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res (2012) 1.11
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med (2011) 1.10
Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum (2003) 1.10
Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol (2006) 1.09
Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol (2009) 1.09
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther (2010) 1.09
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother (2009) 1.08
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther (2006) 1.08
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol (2012) 1.08
The impact of pain and symptoms of depression in scleroderma. Pain (2002) 1.08
Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol (2002) 1.08
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol (2010) 1.08
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis (2013) 1.06